A prospective, randomized, double-blind, controlled clinical study of Panax notoginseng in the treatment of acute ischemic stroke

onghua Hospital affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1) Patients who meet the diagnosis of acute ischemic stroke and TOAST classification does not belong to cardiogenic cerebral embolism (SE);
•2) The onset time <=72 hours (within 72 hours from onset to random drug use);
•3) Persons between 18 and 85 years of age, regardless of gender;
•4) Patients with recurrent onset of first onset or sequela of limb paralysis with mRS score 0 ~ 1 points of previous cerebrovascular disease;
•5) NIHSS score 4 to 25, mild, moderate, and severe patients;
•6) Those who voluntarily accept the drug treatment and sign the informed consent.

•1) Those who do not meet the inclusion criteria;
•2) Patients with transient ischemic attack, lacunar cerebral infarction with non-responsible lesions, cerebral hemorrhage after cerebral infarction, subarachnoid hemorrhage and posterior circulation ischemia;
•3) Hemiplegia caused by brain tumors, brain trauma, brain host worms, metabolic disorders, cerebral embolism caused by rheumatic heart disease, coronary heart disease and other heart diseases combined with atrial fibrillation after examination;
•4) Thrombolytic patients;
•5) Patients with digestive tract ulcers who cannot take aspirin;
•Those with bleeding tendency;
•Patients with severe primary diseases such as cardiovascular disease, liver (ALT or AST > 1.5 ULN, kidney (eGFR < 60), endocrine system and hematopoietic system;
•6) Pregnant and lactating women;
•7) Those who are known to be allergic to the drugs used;
•8) Those who are participating in other drug clinical trials or have participated in other clinical trials within 3 months;
•9) Patients whom the investigator considers inappropriate to participate in a clinical trial.

发起方

onghua Hospital affiliated to Shanghai University of Traditional Chinese Medicine